Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q3 2024 · 10-Q
Revenue$9.09M$9.09M−9.9% vs Q3 2023 Net Income-$1.54M-$1.54MN/M vs Q3 2023 EPS Diluted-$0.11-$0.11N/M vs Q3 2023 Operating Income-$1,694,432N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$460,124−61.1% Margins · derivedOperating margin-18.6%−0.1 pt vs Q3 2023
Net margin-17.0%−6.6 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 8, 2024 · 39 d after period end